DEA Controlled Substances on the UMPJE: What You Need to Know
Controlled substances represent approximately 30% of the UMPJE - the largest single domain on the exam. Based on the NABP content outline, Domain 1 covers federal DEA regulations and broadly applicable CS law in depth.
The good news: DEA rules are highly structured. The same regulations, timelines, and documentation requirements appear repeatedly across different scenario types. Master the framework once, and it applies across a large portion of the exam.
Download the official UMPJE Content Outline at nabp.pharmacy for the authoritative breakdown of what Domain 1 covers.
What Domain 1 Actually Tests
Domain 1 is not a general "controlled substances knowledge" category. It tests specific federal DEA rules applied to real pharmacy scenarios - the same scenario-based format as the rest of the exam.
Based on the NABP content outline, Domain 1 subdomain topics include:
- CS scheduling and classification
- DEA registration requirements and exceptions
- Valid prescription requirements for controlled substances
- Prescribing authority - who can prescribe what, and under what conditions
- Dispensing requirements by schedule
- CS recordkeeping and inventory requirements
- DEA forms and their purposes
- Electronic prescribing for controlled substances (EPCS)
- CS disposal and destruction
- Opioid-specific regulations - CARA, MATE Act, telemedicine prescribing
Each of these appears as a scenario. Not "what is DEA Form 222 used for?" - but "a pharmacy receives a faxed order for a Schedule II - what is the pharmacist required to do?"
The CS Scheduling Framework
Know which schedule means what, and what that schedule dictates for prescribing and dispensing.
| Schedule | Criteria | Federal Refill Rules | Common Examples |
|---|---|---|---|
| CII | High abuse potential, accepted medical use, severe dependence risk | No refills - new Rx required each time | Oxycodone, amphetamine, fentanyl, methadone |
| CIII | Less abuse potential than CII, accepted medical use | Up to 5 refills within 6 months from date issued | Buprenorphine/naloxone combinations, some codeine products |
| CIV | Lower abuse potential than CIII | Up to 5 refills within 6 months from date issued | Benzodiazepines, zolpidem, tramadol |
| CV | Lowest abuse potential of scheduled drugs | Up to 5 refills within 6 months (federal); state laws vary | Some cough preparations with limited codeine |
Key UMPJE principle: When federal and state law conflict on scheduling or restrictions, apply the stricter standard.
Note: Some states impose additional restrictions on specific schedules beyond federal minimums. The UMPJE tests the federal framework and broadly uniform principles - not state-specific additions.
DEA Registration: Core Rules
Every DEA registration scenario on the UMPJE connects to a few foundational rules:
- Practitioners must be registered with the DEA to prescribe, dispense, or administer controlled substances
- Registration is state-specific - a DEA registration authorizes CS activity in the state where the registrant is located
- Hospital residents and employees can prescribe under the hospital's DEA registration in many circumstances - this is a recurring UMPJE scenario type
- Pharmacies require a separate DEA registration from the individual pharmacist
- Mid-level practitioners (NPs, PAs) can prescribe CS under applicable state and federal authority - the UMPJE tests the federal framework
DEA Forms: Know These
These form numbers and purposes appear in UMPJE scenarios. Know which form is used for which purpose without hesitation.
| Form | Purpose |
|---|---|
| DEA Form 222 | Ordering Schedule I and II controlled substances |
| DEA Form 41 | Destruction/disposal of controlled substances |
| DEA Form 106 | Reporting theft or significant loss of CS |
| DEA Form 224 | New pharmacy DEA registration |
| DEA Form 363 | Narcotic treatment program registration |
Most commonly tested: Form 222 (when required, who can sign, what happens if lost or damaged), Form 106 (when a loss is "significant" and requires DEA notification versus routine internal documentation).
These are federal DEA forms. Requirements come from 21 CFR and DEA regulations - always verify current requirements at dea.gov for the most up-to-date versions.
Valid CII Prescription Requirements
Per federal law, a valid Schedule II prescription must include:
- Patient's full name and address
- Date issued
- Drug name, strength, and quantity
- Directions for use
- Prescriber's name, address, and DEA registration number
- Prescriber's manual signature
What corrections are permitted?
Federal regulations permit pharmacists to make certain technical corrections on non-CII prescriptions with prescriber authorization. For Schedule II prescriptions, the rules are stricter. Knowing the specific items a pharmacist may and may not correct - and what requires a new prescription - is a tested UMPJE scenario type.
EPCS: Electronic Prescribing for Controlled Substances
EPCS is testable on the UMPJE because it involves specific regulatory requirements many candidates have not studied:
- DEA regulations require EPCS systems to use two-factor authentication for prescriber identity verification
- Both the prescribing and dispensing software must meet DEA technical standards
- EPCS does not change the validity requirements for a CS prescription - all required elements must still be present
- Some states have additional EPCS requirements layered on top of federal requirements - the UMPJE tests the federal framework
For current EPCS regulations, refer to 21 CFR Part 1311.
CARA and the MATE Act
These are current federal laws that appear in UMPJE scenarios:
CARA (Comprehensive Addiction Recovery Act of 2016):
- Expanded prescribing authority for nurse practitioners and physician assistants to prescribe buprenorphine for opioid use disorder (OUD)
- Authorized pharmacists to dispense naloxone under a standing order in many circumstances under applicable state law
MATE Act (Medication Access and Training Expansion Act, enacted December 2022):
- Eliminated the separate DEA "X-waiver" that previously limited buprenorphine prescribing for OUD
- Added a one-time 8-hour training requirement for DEA-registered practitioners who prescribe Schedule III-V opioids - or who hold a DEA registration and are seeking to prescribe such medications
- All new DEA applicants and renewal applicants after June 27, 2023 must attest to completion of this training
For current MATE Act requirements, see DEA guidance and 21 U.S.C. ยง 823(g).
Telemedicine and CS:
The intersection of telemedicine and controlled substance prescribing - particularly post-COVID DEA rulemaking - is an active and testable area. Know the current federal framework, particularly for buprenorphine and Schedule III-V medications prescribed via telemedicine. Regulations in this area have been subject to active DEA rulemaking as of 2024-2026.
CS Inventory Requirements
Per federal DEA regulations:
- Biennial inventory required - every 2 years
- Inventory may be taken on any date that falls within 2 years of the prior inventory
- Schedule II drugs must be counted exactly
- Schedule III-V drugs may be estimated if the original container holds more than 1,000 units - otherwise an exact count is required
- CS records must be maintained for 2 years and be readily retrievable for DEA inspection
Source: 21 CFR Part 1304
Key Numbers to Have Memorized
These specific numbers and rules appear in UMPJE scenarios consistently. Drill them until they are automatic - not reviewed the night before.
| Rule | Requirement |
|---|---|
| CIII-CV maximum refills | 5 refills |
| CIII-CV prescription validity | 6 months from date written |
| CII refills | Not permitted federally |
| CS records retention | 2 years, readily retrievable |
| Biennial inventory frequency | Every 2 years |
| MATE Act training requirement | 8 hours, one-time |
| DEA Form 222 copies | 3-part form (copy 1: purchaser; copy 2: forwarded to DEA; copy 3: supplier) |
Note: Some states impose stricter timelines or requirements than federal minimums. The UMPJE tests the federal baseline. Always confirm current federal requirements at dea.gov.
Practice These Rules in Scenarios
The most effective way to lock in DEA content is through scenario-based practice - not re-reading the regulations. Pharmacy Decoder has a heavy concentration of questions in Domain 1 to reflect the exam's weighting, with Smart Insights that show your accuracy by specific subdomain.
Pharmacy Decoder is an independent prep resource. Not affiliated with or endorsed by NABP or the DEA.
DEA Controlled Substances UMPJE FAQs
What percentage of the UMPJE is DEA and controlled substances?
Based on the NABP UMPJE Content Outline, Domain 1 (Controlled Substances) accounts for approximately 30% of the exam - the largest single domain. Mastering federal DEA rules is the highest-use preparation step for improving your UMPJE score.
Do I need to know DEA form numbers for the UMPJE?
Yes. DEA Forms 222, 41, and 106 are among the most commonly tested - not as definitions, but as scenario elements. ("A pharmacy discovers a discrepancy in its Schedule II inventory - which form is required?") Know the forms and their purposes without hesitation.
Does the UMPJE test the MATE Act?
Yes. The MATE Act (2022) eliminated the X-waiver and added an 8-hour training requirement for DEA registrants who prescribe Schedule III-V opioids. It is current federal law and fully testable. Confirm your preparation materials cover it - some older resources predate the MATE Act.
What CS schedules are most commonly tested on the UMPJE?
Schedule II is the most heavily tested - refill restrictions, documentation requirements, valid prescription elements, and prescribing authority scenarios are concentrated in CII. CIII-CV refill rules and the 6-month validity window are also frequently tested.
Is telemedicine prescribing of controlled substances tested?
Yes. The intersection of telemedicine and CS prescribing - particularly for buprenorphine and Schedule III-V medications - is a current, testable area. Know the federal framework including CARA provisions and current DEA guidance on telemedicine prescribing. This area has been subject to active regulatory activity and may be updated - verify with current DEA and HHS guidance.